Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
NCT ID: NCT04431791
Last Updated: 2020-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
268 participants
OBSERVATIONAL
2020-05-25
2022-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
NCT04296019
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
NCT06202417
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
NCT05447715
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
NCT07261709
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
NCT05634590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Regorafenib
Regorafenib
oral regorafenib
Fruquintinib
Fruquintinib
oral fruquintinib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Regorafenib
oral regorafenib
Fruquintinib
oral fruquintinib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of histologically confirmed colorectal cancer, stage IV.
3. after second-line therapy.
4. gastrointestinal physician prescribed to receive regorafenib or fruquintinib according the patients' condition.
Exclusion Criteria
2. the clinicopathological characteristics and previous therapy were unknown.
3. regorafenib or fruquintinib treatment is less than one cycle in the historical cohort.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shen Lin
MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Reg vs Fru
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.